56O A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB (T3N2) non-small-cell lung cancer. (December 2022) - Lei, J.; Zhao, J.; Yan, X.; Gong, L.; Lei, G.; Jiang, T.